On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International's Vaccines Unit Worth $635 Million

Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015 November 17, 2014 Pfizer Inc. announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to …

EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy April 7, 2014 EMD Serono, Inc., a subsidiary of Merck KGaA, …

Potential Lung Cancer Vaccine Shows Renewed Promise

March 20, 2014 Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an …

Therapeutic Cancer Vaccines: The failures

Cancer immunotherapy and cancer vaccines were named Science Magazine’s ‘Breakthrough of the Year 2013‘, but whilst the industry continues to be optimistic about the promises of harnessing a patients immune system to treat cancer, it’s hard to ignore the big disappointments that have been recorded in a number of high profile Phase III and II trial failures. Here are just …